KLRS Allovir, Inc.

Nasdaq allovir.com


$ 5.23 nm (nm)    

Thursday, 13-Nov-2025 15:59:53 EST
QQQ $ 608.18 $ -12.68 (-2.04 %)
DIA $ 475.16 $ -8.02 (-1.66 %)
SPY $ 672.28 $ -11.34 (-1.66 %)
TLT $ 89.53 $ -0.74 (-0.82 %)
GLD $ 383.58 $ -3.12 (-0.81 %)
$ 4.96
$ 4.90
$ 4.65 x 100
$ 5.55 x 1
$ 4.87 - $ 5.45
$ 2.14 - $ 15.63
78,536
na
92.76M
$ 1.41
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-07-2025 01-01-1970 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-09-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 03-15-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-15-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-10-2022 12-31-2021 10-K
17 11-05-2021 09-30-2021 10-Q
18 08-06-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-12-2021 12-31-2020 10-K
21 11-10-2020 09-30-2020 10-Q
22 09-02-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of ...

Core News & Articles

Citizens analyst Jonathan Wolleben initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Market Outperform rating ...

Core News & Articles

Kalaris Therapeutics ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercia...

Core News & Articles

Raymond James analyst Chris Raymond initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Strong Buy rating and an...

Core News & Articles

Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION